Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr 15;83(8):1033-40.
doi: 10.1016/j.bcp.2011.12.017. Epub 2011 Dec 24.

NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones

David Siegel  1 , Chao Yan, David Ross
Affiliations
Review

NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones

David Siegel et al. Biochem Pharmacol. .

Abstract

Quinones represent a large and diverse class of antitumor drugs and many quinones are approved for clinical use or are currently undergoing evaluation in clinical trials. For many quinones reduction to the hydroquinone has been shown to play a key role in their antitumor activity. The two-electron reduction of quinones by NQO1 has been shown to be an efficient pathway to hydroquinone formation. NQO1 is expressed at high levels in many human solid tumors making this enzyme ideally suited for intracellular drug activation. Cellular levels of NQO1 are influenced by the NQO1*2 polymorphism. Individuals homozygous for the NQO1*2 allele are NQO1 null and homozygous NQO1*2*2 cell lines have been shown to be more resistant to antitumor quinones when compared to isogenic cell lines overexpressing NQO1. In this review we will discuss the role of NQO1 in the sensitivity and resistance of human cancers to the quinone antitumor drugs mitomycin C, β-lapachone and the benzoquinone ansamycin class of Hsp90 inhibitors including 17-AAG. The role of NQO1 in the bioreductive activation of mitomycin C remains controversial but pre-clinical data strongly suggests a role for NQO1 in the activation of β-lapachone and the benzoquinone ansamycin class of Hsp90 inhibitors. Despite a large volume of preclinical data demonstrating that NQO1 is an important determinant of sensitivity to these antitumor quinones there is little information on whether the clinical response to these agents is influenced by the NQO1*2 polymorphism. The availability of simple assays for the determination of the NQO1*2 polymorphism should facilitate clinical testing of this hypothesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of mitomycin C, β-lapachone and 17-AAG The quinone moiety is highlighted in red. 17-AAG, 17-N-allylamino-17-demethoxygeldanamycin.
Figure 2
Figure 2
Pathways for bioreductive activation of antitumor quinones by NQO1 (ROS, reactive oxygen species).
Figure 3
Figure 3
The role of NQO1 in the bioactivation of mitomycin C and β-lapachone. (A) Reduction of MMC by NQO1 generates leucomitomycin C (MMC hydroquinone) which under basic conditions alkylates NQO1 in the active site preventing further metabolism. Under acidic conditions, the leucomitomycin C escapes the active site in NQO1 and can alkylate important biomolecules such as DNA or form the major metabolite 2,7-diaminomitosene (2,7-DAM); (B) Reduction of β-lapachone by NQO1 forms an unstable hydroquinone which interacts with molecular oxygen to generate reactive oxygen species leading to apoptosis.
Figure 4
Figure 4
The Role of NQO1 in potentiating the antitumor activity of benzoquinone ansamycins. Solid lines represent major pathways. Dashed lines represent minor pathways. BQA, benzoquinone ansamycin quinone; BQAH2, benzoquinone ansamycin hydroquinone; BQA-GS, benzoquinone ansamycin quinone-glutathione conjugate; Hsp90, heatshock 90 protein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics. 2006;2:329–335. - PMC - PubMed
    1. Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol. 1990;186:287–301. - PubMed
    1. Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, et al. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci U S A. 2000;97:3177–3182. - PMC - PubMed
    1. Bianchet MA, Faig M, Amzel LM. Structure and mechanism of NADP.H:quinone acceptor oxidoreductases (NQO) Methods Enzymol. 2004;382:144–174. - PubMed
    1. Winski SL, Koutalos Y, Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res. 2002;62:1420–1424. - PubMed

MeSH terms